On one side, Roche’s drug, already established and distributed globally; on the other, its first generic version ready to enter the U.S. market. The authorization by the Food and Drug Administration (FDA) granted to Norwich Pharmaceuticals’ baloxavir marboxil marks the beginning of a new phase for Xofluza, a single-dose antiviral against influenza, now at the center of direct competition between the originator and generic ahead of the 2026–2027 flu season.
FDA APPROVAL
The decision of the U.S. regulatory agency concerns baloxavir marboxil tablets produced by Norwich Pharmaceuticals, authorized as the first generic equivalent of the single-dose treatment indicated for uncomplicated acute influenza and for post-exposure prevention in patients aged 5 and older. The agency emphasized that the drug can be used in cases where symptoms have been present for no more than 48 hours and in subjects both healthy and at risk of complications.
Commenting on the approval, Iilun Murphy, director of the Office of Generic Drugs at the Center for Drug Evaluation and Research, stated that the authorization represents “a significant milestone in the treatment of influenza” and that “expanding patient access to medications and improving ease of use are fundamental priorities for public health.”
THE DRUG AND CLINICAL USE
Baloxavir marboxil tablets are indicated for the treatment of uncomplicated acute influenza in patients over 5 years old with recent symptoms and for prophylaxis after exposure to infected individuals. Clinical use is based on a single oral dose administration, a feature that has contributed to the drug’s spread across various healthcare systems.
According to regulatory information, the active ingredient is contraindicated in cases of known hypersensitivity and notes a potential increase in emerging resistance in younger patients, particularly under 5 years old. The most frequently reported adverse effects include gastrointestinal disorders, respiratory infections, and symptoms such as headache and sinusitis.
ORIGIN AND POSITIONING OF XOFLUZA
Xofluza, the brand name of baloxavir marboxil, was developed as an innovative antiviral with a mechanism of action targeting the inhibition of the cap-dependent endonuclease protein, essential for influenza virus replication. The drug has been described as the first belonging to a class designed to intervene in this specific biological process.
Roche highlighted that the medicine has shown activity against various influenza strains, including oseltamivir-resistant strains and avian-origin variants such as H7N9 and H5N1, based on non-clinical studies. The drug is approved in the United States for the treatment of uncomplicated acute influenza and for patients at high risk of complications, while it is authorized in over 80 countries for type A and B influenza infections. Initial development was attributed to Shionogi & Co., Ltd., with subsequent global collaboration with Roche, which holds international rights outside Japan and Taiwan.
WHAT IT MEANS FOR ROCHE
The entry of Norwich Pharmaceuticals into the market with a generic version of Xofluza introduces a direct competitive dynamic on a product originally marketed by Roche through the Genentech division in the United States. The regulatory context highlights how the generic sector represents a predominant share of prescriptions in the U.S. market, with about 9 out of 10 drugs dispensed belonging to this category.
WHAT NORWICH PHARMACEUTICALS DOES
Norwich Pharmaceuticals operates as a development, manufacturing, and packaging company and is part of the Alvogen group, with activities including contract manufacturing and development of generic versions of branded drugs. The approval of its product fits into the strategy of expanding the generic drug offering, with direct effects on the commercial availability of the active ingredient baloxavir marboxil in the U.S. market and on the position of Roche’s original product in the single-dose antiviral segment.
